日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

USEUROPEAFRICAASIA 中文雙語(yǔ)Fran?ais
China
Home / China / Business

Medicine trade tops $100b in 2015

By Wang Wen | China Daily | Updated: 2016-02-08 16:03

China's trade in medicines hit an all-time high of $102 billion last year.

The latest figures from the China Chamber of Commerce for Import and Export of Medicines and Health Products show the value was a 4.73 percent increase on 2014, and this year total export-import volumes are expected to rise again, by 3 to 5 percent.

Xu Ming, the chamber's deputy director, called the overall growth "healthy and stable", adding, however, that the Chinese export market had slowed.

Medicine imports were worth $46.2 billion, up 7.3 percent, while exports grew a slower 2.7 percent to $56.4 billion.

"That import growth indicates the Chinese domestic market has huge potential, as it is now the second-largest globally after the United States," said Xu.

The weaker export figures were largely indicative of an ongoing global economic slowdown, Xu said, and coupled with a weaker yuan, they put China on the back foot as an international medicine supplier.

Exports to the US performed well, even though some other main markets dropped. Volumes to the US grew 7.72 percent compared with the previous year and it is now China's second-largest medicine export market after Europe, where demand dropped 0.22 percent.

Xu remains positive that Chinese companies are making strong headway in their moves to expand trade abroad.

Some have been expanding through investment and merger, which is often a more complicated route than simply selling their products directly.

"It's astonishing how some Chinese companies have performed so well in overseas investments," Xu said.

One of the sector's most significant developments in 2015 was by a consortium led by Shanghai Fosun Pharmaceutical Group Co Ltd, which bought Ambrx Inc, a US biotechnology company focusing on molecular medicine.

The acquisition group also involved HOPU Jinghua (Beijing) Investment Consultancy Co Ltd, China Everbright Ltd's healthcare fund, and Wuxi PharmaTech, and the purchase included some valuable global biotechnology.

Fosun Pharma's Chairman Chen Qiyu said the acquisition would "produce a dramatic synergistic effect on Fosun's current development system".

Ambrx is now expected to build a global products development center in China, Chen said.

Other moves saw Chinese companies signing agreements with foreign companies to sell their products overseas.

Jiangsu Heng Rui Medicine Co Ltd, for instance, authorized US-based pharmaceutical company Incyte Corp to develop and sell its PD-1 antibody product outside China in September, with the Delaware firm paying $795 million for the right.

wangwen@chinadaily.com.cn

 

Editor's picks
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 黄色av网站免费 | 久久一区二 | 黄色福利| 九九免费| 国产裸体永久免费无遮挡 | 日本欧美国产 | 欧美日韩在线网站 | 黄色一级大片在线免费看国产一 | 国产一二区视频 | 免费在线不卡视频 | 激情视频在线观看免费 | 日韩一区免费视频 | 国产精品v欧美精品v日韩 | 国产麻豆a毛片 | 99久久99久久 | 午夜免费播放观看在线视频 | 天天草天天干 | 国产午夜精品久久久久 | 国内精品久久久久久久久久久 | 婷婷丁香亚洲 | 免费特级黄毛片 | 成人小视频免费观看 | 久久久久亚洲精品国产 | 日韩第三页| 精品国产精品国产偷麻豆 | 蜜臀久久99精品久久久久久 | 久久久久网站 | 97国产精品久久久 | 91亚洲视频在线观看 | 美日韩三级 | 欧美成人三级视频 | 青青草影视 | 日韩特一级| 高h在线播放| 欧美久久久久久久久中文字幕 | 亚洲视频精品 | 亚洲精品视频二区 | 五月天综合网站 | 在线播放第一页 | 日韩免费黄色片 | 国产精品爽爽久久久久久 |